Seres Therapeutics, Inc. (MCRB) Operating margin 2016–2025
Seres Therapeutics, Inc. (MCRB) operating margin by fiscal year — reported operating income divided by reported revenue.
-11910.1%FY2025 · since FY2016: -426.5% → -11910.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -11910.1% | — |
| FY2022 | -2524.0% | -2479.2 pp |
| FY2021 | -44.8% | +695.9 pp |
| FY2020 | -740.8% | -476.4 pp |
| FY2019 | -264.4% | +108.2 pp |
| FY2018 | -372.6% | -87.8 pp |
| FY2017 | -284.7% | +141.8 pp |
| FY2016 | -426.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More MCRB financial trends
MCRB RevenueMCRB Net incomeMCRB Net marginMCRB Gross profitMCRB Gross marginMCRB Operating incomeMCRB Operating cash flowMCRB Free cash flowMCRB Capital expendituresMCRB Return on equityMCRB Stock buybacksMCRB Dividends paidMCRB Total assetsMCRB Total liabilitiesMCRB Shareholders’ equityMCRB overview →